Johnson & Johnson invests EUR 5.5m in new headquarters in Portugal and new clinical trials unit
|
10 SEP 2018
|
Intel ID : 264501
|
||||
| Intel ID | 264501 | |
| Value | EUR 5,50m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Johnson & Johnson Portugal
(31 Dec 2021) |
Revenue: EUR 106,36m EBITDA: EUR 5,47m Net Debt: EUR 1,55m People: 187 |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
15.04.01 Cosmetics & Perfumes 15 Consumer Products & Services / 15.04 Consumer Nondurables |
||
| Country |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.